U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 106

1.
LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion
Shunta Mori, Hiroki Izumi, Mitsugu Araki, Jie Liu, Yu Tanaka, Yosuke Kagawa, Yukari Sagae, Biao Ma, Yuta Isaka, Yoko Sasakura, Shogo Kumagai, Yuta Sakae, Kosuke Tanaka, Yuji Shibata, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Yasushi Okuno, Koichi Goto, Susumu S. Kobayashi
Commun Biol. 2024; 7: 412. Published online 2024 Apr 4. doi: 10.1038/s42003-024-06116-6
PMCID:
PMC10995188
ArticlePDF–1.1M
2.
Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase‐positive non‐small‐cell lung cancer
Yuki Shimomura, Kenji Sawa, Takumi Imai, Yasutaka Ihara, Hisako Yoshida, Ayumi Shintani
Cancer Sci. 2024 Mar; 115(3): 926–936. Published online 2023 Dec 27. doi: 10.1111/cas.16056
PMCID:
PMC10920989
ArticlePDF–2.1M
3.
CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles
Marc Terrones, Christophe Deben, Felicia Rodrigues-Fortes, Anne Schepers, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer
J Transl Med. 2024; 22: 234. Published online 2024 Mar 3. doi: 10.1186/s12967-024-04988-0
PMCID:
PMC10910754
ArticlePDF–5.1M
4.
Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
Wenjie Liu, Gengwei Huo, Peng Chen
Front Public Health. 2024; 12: 1213318. Published online 2024 Feb 15. doi: 10.3389/fpubh.2024.1213318
PMCID:
PMC10906082
ArticlePDF–710K
5.
Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases
Yosuke Murakami, Yosuke Kawashima, Shinji Chiba, Shuichiro Hara, Yusuke Yamazaki, Tsuyoshi Doman, Shin Saito, Tetsuo Odaka, Takahiro Ogasawara, Hisashi Shimizu, Jun Sugisaka, Tomoiki Aiba, Yukihiro Toi, Shinsuke Yamanda, Yuichiro Kimura, Shunichi Sugawara
Cancer Rep (Hoboken) 2024 Feb; 7(2): e1981. Published online 2024 Jan 11. doi: 10.1002/cnr2.1981
PMCID:
PMC10864716
ArticlePDF–2.3M
6.
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis
Mingye Zhao, Taihang Shao, Hanqiao Shao, Caicun Zhou, Wenxi Tang
BMC Cancer. 2024; 24: 186. Published online 2024 Feb 8. doi: 10.1186/s12885-024-11916-4
PMCID:
PMC10851546
ArticlePDF–3.7M
7.
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
Joseph Chen, Alessandra Bearz, Dong-Wan Kim, Hirva Mamdani, Jessica Bauman, Rita Chiari, Sai-Hong Ignatius Ou, Benjamin J. Solomon, Ross A. Soo, Enriqueta Felip, Alice T. Shaw, Holger Thurm, Jill S. Clancy, Kimberly Lee, Melissa O’Gorman, Cherie Tanski, Yazdi K. Pithavala
Clin Pharmacokinet. 2024; 63(2): 171–182. Published online 2023 Dec 11. doi: 10.1007/s40262-023-01309-4
PMCID:
PMC10847213
ArticlePDF–1.0M
8.
SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
Ivette Valencia-Sama, Lynn Kee, Gabriella Christopher, Michael Ohh, Mehdi Layeghifard, Adam Shlien, Madeline N. Hayes, Meredith S. Irwin
Cancer Res Commun. 2023 Dec; 3(12): 2608–2622. Published online 2023 Dec 27. doi: 10.1158/2767-9764.CRC-23-0234
PMCID:
PMC10752212
ArticlePDF–10M
9.
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
Cesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, Maria Rita Migliorino, Vito Barbieri, Paolo Bironzo, Alessandra Bearz, Ilaria Attili, Filippo de Marinis
Curr Oncol. 2023 Nov; 30(11): 10033–10042. Published online 2023 Nov 20. doi: 10.3390/curroncol30110729
PMCID:
PMC10670405
ArticlePDF–265K
10.
Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report
Jie Li, Junwei Liu, Guqin Zhang, Weidong Hu, Xianguo Wang, Jun Liu
Am J Case Rep. 2023; 24: e942150-1–e942150-5. Published online 2023 Nov 7. doi: 10.12659/AJCR.942150
PMCID:
PMC10642716
ArticlePDF–2.0M
11.
The Exploration of Chirality for Improved Druggability within the Human Kinome
Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, Hong-Yu Li
J Med Chem. Author manuscript; available in PMC 2023 Sep 28.
Published in final edited form as: J Med Chem. 2020 Jan 23; 63(2): 441–469. Published online 2019 Oct 9. doi: 10.1021/acs.jmedchem.9b00640
PMCID:
PMC10536157
ArticlePDF–5.0M
12.
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Geoffrey Liu, Vincent K. Lam
Adv Ther. 2023; 40(10): 4117–4126. Published online 2023 Aug 12. doi: 10.1007/s12325-023-02606-x
PMCID:
PMC10499938
ArticlePDF–244K
13.
A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang
Cancer Med. 2023 Aug; 12(15): 15983–15997. Published online 2023 Jun 19. doi: 10.1002/cam4.6241
PMCID:
PMC10469807
ArticlePDF–3.8M
14.
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
Martin Rupp, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, Shoghag Khoudigian, Arushi Sharma, Phu Vinh On, Geoffrey Liu
Curr Oncol. 2023 Jul; 30(7): 6559–6574. Published online 2023 Jul 8. doi: 10.3390/curroncol30070481
PMCID:
PMC10377946
ArticlePDF–1.7M
15.
Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
Xiya Ma, Kun Zhang, Jing Xu, Hongjun Gao, Shaoxing Yang, Haifeng Qin, Hong Wang, Fang Gao, Xiaoqing Liu
Thorac Cancer. 2023 Jul; 14(20): 1980–1990. Published online 2023 Jun 2. doi: 10.1111/1759-7714.14980
PMCID:
PMC10344744
ArticlePDF–1.1M
16.
Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
Yujin Suk, Sheila K. Singh
Cell Rep Med. 2023 Jun 20; 4(6): 101071. Published online 2023 Jun 20. doi: 10.1016/j.xcrm.2023.101071
PMCID:
PMC10313925
ArticlePDF–200K
17.
Real‐world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer
Yasushi Goto, Takehito Shukuya, Ai Murata, Hironori Kikkawa, Birol Emir, Robin Wiltshire, Satoru Miura
Cancer Sci. 2023 Jun; 114(6): 2560–2568. Published online 2023 Apr 2. doi: 10.1111/cas.15777
PMCID:
PMC10236600
ArticlePDF–611K
18.
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden
Jaesh Naik, Norma Beavers, Fredrik O. L. Nilsson, Laura Iadeluca, Chrissy Lowry
Appl Health Econ Health Policy. 2023; 21(4): 661–672. Published online 2023 May 12. doi: 10.1007/s40258-023-00807-7
PMCID:
PMC10232573
ArticlePDF–829K
19.
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
Kelly C. Goldsmith, Julie R. Park, Kimberly Kayser, Jemily Malvar, Yueh-Yun Chi, Susan G. Groshen, Judith G. Villablanca, Kateryna Krytska, Lillian M. Lai, Patricia T. Acharya, Fariba Goodarzian, Bruce Pawel, Hiroyuki Shimada, Susan Ghazarian, Lisa States, Lynley Marshall, Louis Chesler, Meaghan Granger, Ami V. Desai, Rajen Mody, Daniel A. Morgenstern, Suzanne Shusterman, Margaret E. Macy, Navin Pinto, Gudrun Schleiermacher, Kieuhoa Vo, Holger C. Thurm, Joseph Chen, Marlon Liyanage, Gerson Peltz, Katherine K. Matthay, Esther R. Berko, John M. Maris, Araz Marachelian, Yael P. Mossé
Nat Med. 2023; 29(5): 1092–1102. Published online 2023 Apr 3. doi: 10.1038/s41591-023-02297-5
PMCID:
PMC10202811
ArticlePDF–4.6M
20.
Lorlatinib for ALK‐fused, infant‐type hemispheric glioma with lung metastasis: a case report
Mingyao Lai, Shaoqun Li, Hainan Li, Qingjun Hu, Juan Li, Jiangfen Zhou, Ruyu Ai, Junjie Zhen, Zhaoming Zhou, Lichao Wang, Yangqiong Zhang, Wanming Hu, Li Yuan, Xuejiao Ma, Xing Zhang, Chao Song, Zhi Li, Linbo Cai
Ann Clin Transl Neurol. 2023 May; 10(5): 836–841. Published online 2023 Mar 31. doi: 10.1002/acn3.51766
PMCID:
PMC10187722
ArticlePDF–1.9M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center